EUVIMEDEUVIMED entdecken
Open Access

Estimating the Effects of MTEER in U.S. Practice

Christina Lalani, Neel Butala, Huaying Dong, Yang Song, Gregg W Stone, Michael J Mack, Bahira Shahim, Dhruv S Kazi, David J Cohen, Issa J Dahabreh, Robert W Yeh

JACC · 2026

DOI: 10.1016/j.jacc.2026.04.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC, 2026. Verfasst von Christina Lalani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Richard A. and Susan F. Smith Cente…. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Cardiac Catheterization, Mitral Valve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NLM NIH HHS, NHLBI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although mitral transcatheter edge-to-edge repair (MTEER) was approved for secondary mitral regurgitation after the COAPT trial, findings of other MTEER trials have been mixed, raising questions about the applicability of the COAPT results to contemporary clinical practice. OBJECTIVES: We used transportability methods to estimate the treatment effects of COAPT trial interventions applied to 2 target populations: 1) trial-eligible patients representative of U.S. clinical practice; and 2) treatment-candidate patients with secondary mitral regurgitation representative of U.S. clinical practice, regardless of trial eligibility. METHODS: We identified patients from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry who were treated with MTEER for secondary mitral regurgitation from March 14, 2019 to September 30, 2023. To select trial-eligible individuals, we applied COAPT trial eligibility criteria to the TVT Registry sample. We used inverse odds of participation weighting to standardize patient-level COAPT data to the data distribution of each target population sample and estimated treatment-specific outcomes. The primary outcome was heart failure hospitalization at 2 years. We also examined 10 secondary outcomes, including all-cause death. RESULTS: Our analyses included 614 COAPT trial patients and 15,275 TVT Registry patients, of which 7,289 were COAPT trial-eligible. Trial-eligible TVT Registry patients were less likely to have ischemic cardiomyopathy (34.1% vs 60.8%) and more likely to have 4+ mitral regurgitation (79.4% vs 47.9%) compared with trial patients. We estimated that compared with medical therapy alone, MTEER in conjunction with other COAPT interventions (eg, optimization of medical therapy) in the trial-eligible population would result in 2-year absolute risk reductions of 17.0% for heart failure hospitalizations (95% CI: -28.7% to -5.7%) and 15.4% for all-cause death (95% CI: -26.6% to -5.2%), effect sizes similar to those estimated in the trial (P for difference between the trial and target populations >0.05 for both outcomes). The estimated treatment effect for heart failure hospitalizations in the broader treatment-candidate target population was also similar to that in the COAPT trial (P for difference = 0.90). CONCLUSIONS: Although COAPT trial patients had different baseline characteristics than patients undergoing MTEER in contemporary U.S. practice, we estimated that treatment effects would be similar had real-world patients received COAPT trial interventions, under the assumptions required for transportability (eg, conditional exchangeability across data sources, positivity of trial participation).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyCardiac CatheterizationMitral ValveHumansUnited StatesFemaleRegistriesMaleAgedHeart FailureTreatment OutcomeAged, 80 and overHospitalization

Stichwörter der Autor:innen

COAPTTVT Registryreal-worldtransportability

Autor:innen und Institutionen

  • Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA; Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard…
  • Division of Cardiology, Rocky Mountain Regional VA Medical Center, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • The Heart Hospital Plano, Baylor Scott & White, Plano, Texas, USA.
  • Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Förderung

  • NHLBI NIH HHS
  • NLM NIH HHS
  • NHLBI

Zitieren

APA

Lalani, C., Butala, N., Dong, H., Song, Y., Stone, G. W., Mack, M. J., Shahim, B., Kazi, D. S., Cohen, D. J., Dahabreh, I. J., & Yeh, R. W. (2026). Estimating the Effects of MTEER in U.S. Practice. JACC. https://doi.org/10.1016/j.jacc.2026.04.025

Vancouver

Lalani C, Butala N, Dong H, Song Y, Stone GW, Mack MJ, et al. Estimating the Effects of MTEER in U.S. Practice. JACC. 2026. doi:10.1016/j.jacc.2026.04.025

BibTeX
@article{Lalani2026,
  author = {Lalani, Christina and Butala, Neel and Dong, Huaying and Song, Yang and Stone, Gregg W and Mack, Michael J and Shahim, Bahira and Kazi, Dhruv S and Cohen, David J and Dahabreh, Issa J and Yeh, Robert W},
  title = {Estimating the Effects of MTEER in U.S. Practice},
  journal = {JACC},
  year = {2026},
  doi = {10.1016/j.jacc.2026.04.025}
}
Kostenlos starten →